Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure

Annals of Hematology

Volumn 94, Issue 3, 2015, Pages 501-503

  Hai, Jo Jo ^a   Gill, Harinder ^a   Tse, Hung Fat ^a   Kumana, Cyrus R ^b   Kwong, Yok Lam ^a   Siu, Chung Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE;

AGED; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; HEART FAILURE; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; ORAL DRUG ADMINISTRATION; TORSADES DE POINTES;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; HEART FAILURE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; OXIDES; TORSADES DE POINTES;

EID: 84927566218     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2174-1     Document Type: Letter

References (13)

1. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10):3315–3324
2. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol: Off J Am Soc Clin Oncol 19(18):3852–3860
3. Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol: Off J Am Soc Clin Oncol 21(19):3609–3615
4. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133(11):881–885
5. Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW, Kwong YL (2002) Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 58(8):521–526
6. Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL, Tse HF (2006) Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 108(1):103–106
7. Kathirgamanathan K, Angaran P, Lazo-Langner A, Gula LJ (2013) Cardiac conduction block at multiple levels caused by arsenic trioxide therapy. Can J Cardiol 29(1):130–e135-136
8. Drolet B, Simard C, Roden DM (2004) Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109(1):26–29
9. Hai JJ, Siu CW, Ho HH, Li SW, Lee S, Tse HF (2010) Relationship between changes in heart rate recovery after cardiac rehabilitation on cardiovascular mortality in patients with myocardial infarction. Heart Rhythm: Off J Heart Rhythm Soc 7(7):929–936
10. Siu CW, Pong V, Jim MH, Yue WS, Ho HH, Li SW, Lau CP, Tse HF (2010) Beta-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function. Pacing Clin Electrophysiol: PACE 33(6):675–680
11. Yeung CY, Lam KS, Li SW, Lam KF, Tse HF, Siu CW (2012) Sudden cardiac death after myocardial infarction in type 2 diabetic patients with no residual myocardial ischemia. Diabetes Care 35(12):2564–2569
12. Siu CW, Pong V, Ho HH, Liu S, Lau CP, Li SW, Tse HF (2010) Are MADIT II criteria for implantable cardioverter defibrillator implantation appropriate for Chinese patients? J Cardiovasc Electrophysiol 21(3):231–235
13. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG (2007) Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 153(6):891–899